Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + F1174I o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Commun
Hlavní autoři: Mizuta, Hayato, Okada, Koutaroh, Araki, Mitsugu, Adachi, Jun, Takemoto, Ai, Kutkowska, Justyna, Maruyama, Kohei, Yanagitani, Noriko, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Friboulet, Luc, Katayama, Kazuhiro, Ma, Biao, Sasakura, Yoko, Sagae, Yukari, Kukimoto-Niino, Mutsuko, Shirouzu, Mikako, Takagi, Satoshi, Simizu, Siro, Nishio, Makoto, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904790/
https://ncbi.nlm.nih.gov/pubmed/33627640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21396-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky